AKR1C18 Inhibitors

Inhibitors of AKR1C enzymes typically work by binding to the active site of the enzyme, thereby preventing the binding and reduction of substrates such as steroid hormones, prostaglandins, and other carbonyl-containing compounds. The AKR1C family is known to be involved in the inactivation and activation of hormones and is also implicated in the metabolism of xenobiotics, which are foreign organic compounds such as drugs and toxins.

The chemical inhibitors listed may act through competitive inhibition, where they compete with the natural substrate for binding to the active site. Alternatively, they may induce conformational changes in the enzyme that result in a decrease in enzymatic activity. Given that these enzymes play a role in a variety of physiological processes, inhibitors can affect the balance of hormones and contribute to the regulation of biological pathways influenced by these hormones. While NSAIDs are primarily known for their anti-inflammatory effects, some of them have been found to inhibit AKR1C enzymes as an off-target effect. This off-target pharmacological activity can alter the levels of active steroid hormones and prostaglandins, which are substrates of the AKR1C enzymes. Thus, the inhibitors listed above may impact the biological functions where AKR1C enzymes, including AKR1C18, are involved.